OTCBB FOREX Company FXIT

I have traded FOREX and it is a very interesting thing to do.  However, I must warn that it is very nerve racking! This company looks pretty interesting and I am adding it to my watch list.

"Darren Dunckel, Chief Executive Officer of the Company stated: "Moving onto the OTCBB market is an important step in the growth of our Company as it brings the Company to the forefront of the public markets. I am excited by several opportunities that are being presented as a result of our reaching this milestone, and I believe these opportunities will help accelerate the execution of our business plan. A key aspect of our strategy moving forward is to efficiently and effectively communicate corporate developments to our shareholders.”

Always consult a registered investment adviser before making an investment decision. Penny stocks are very risky,investing in pennystocks can result in entire loss of investment.

Penny Stock ACTC Shares Jump on Excitement

Penny stock ACTC has had a very nice run over the last week.  The share price has increased from around five cents to fifteen cents. Shareholders of ACTC have to be doing the stock dance, but will it continue? I have seen this in the past, the buying drys up, and the share price falls.  I wonder just how much ACTC stock will appreciate?  Perhaps this will be one of those penny stock which runs from pennies to over a dollar.  Please refer to my previous posts about ACTC.

Penny stocks are risky investments, and anyone considering investment in them should do so knowing their entire investment could be lost.  Only make investments with the advice of a registered investments advisor.

BLSP Stock News: OTCBB Pennystocks

"Blue Sphere Corp. Submits Product Identification Note for One of its Projects in Ghana

Dec. 2, 2010 (Filing Services Canada) -- Blue Sphere Corporation (BLSP - OTCBB stock news),(the 'Company' or 'Blue Sphere'), a company in the Cleantech sector as an Emission Reduction project integrator, is pleased to announce that it has submitted the Project Identification Note ('PIN') to the Ghanaian government for preliminary approval of its landfill gas mitigation clean development mechanism ('CDM') project in Accra, Ghana.


Otcbb News and Information About the OTCBB trading platform, and listing information.

Penny stock Information Learn more about how penny stocks generally trade, and how to avoid the big mistakes.

Twitter, and Facbook Investorrelations solutions! Improve your company significantly!

BLSP stock message board More about BLSP, Charts, News

Pink sheet listing, and trading information. Learn about pink-sheet-stocks, and how they can help your company grow.

The same old promises in investor relations are not working! We know why, and we will deliver excellent results using social media. Facebook, and Twitter are two of many tools in social media which are being used to deploy successful investor-relations initiatives. We know how to use social-media to deliver results in investor relations for OTCBB, pennystocks, and pink sheets! Call us when your company is ready for great products and superb investor relations! Visit GroupVenture, DONT'T fall for the same old garbage, promise the world, and deliver nothing programs. We won't promise the world, but we will deliver results!

OTCBB Pennystock, GTHP Stock News

"FDA Accepts Guided Therapeutics' Non-Invasive Cervical Cancer Scanner PMA Application for Review

Dec. 2, 2010 (Business Wire) -- Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP stock news) announced that it was notified by the U.S. Food and Drug Administration (FDA) that the company’s premarket approval application (PMA) for the LightTouch™ Cervical Scanner, for patients at risk for cervical cancer, is “suitable for filing.”

GTHP Message Board News, Charts, and More on GTHP

OTCBB Stock News and Information About the OTCBB trading platform, and listing information.

Penny Stocks Trading help Learn about how penny stocks generally trade, and how to avoid the big mistake.

Pink Sheets Listing, and Trading Information. Learn about the pink sheet stocks, and how they can help your company move forward.

Twitter, and Facebook strategies for Investor Relations. Sick of holding issued stock you don't want?

The same old crap in investor relations is not working! We know why, and we can help deliver outstanding results using social media. Twitter and Facebook are only two of the many outlets of socialmedia being used to deploy investor relations successfully. We know how to use social media to deliver results in investor relations for penny stocks, OTCBB, and pink sheets! Give us a call if your company has great products and poor investor relations! Visit GroupVenture, DONT'T fall for the same old crap, promise the world, and deliver nothing programs. We're not promising the world, but we will deliver!

Penny Stocks, DIGA Wins Case

In a unanimous jury verdict DIGA win case brought by former CEO Michael Krawitz.  The jury declined to make an award in the case.

“We are pleased to be able to put this baseless lawsuit behind us,” commented Digital Angel CEO Joseph J. Grillo. “This case, along with other legacy issues inherited from prior management, has been an enormous drain on current management’s time and resources and we are gratified that the jury found the lawsuit’s claims to be without merit by granting the Company an unqualified victory in the matter. This will be one less distraction for us as we continue to focus on improving the operational and financial performance of the Company.”

Always consult a registered investment advisor before making an investment. Penny stocks are very risky and can result in entire loss of investment.

IRE I Almost Bought, Buy, Sell, Hold?

I thought I was going to get to take a risk on IRE  at the close yesterday, for some reason I decided against it.  However, I immediately regretted not buying it when news surfaced that pushed shares of IRE back to $2. This mornings opening looks to put my regret in check, in a sudden reverse shares of IRE are now down further than before yesterdays close.
News that the Irish government will increase its holdings in IRE and likely dilute an already battered stock. Is IRE oversold at these levels? Assuming that IRE, and Europe altogether will emerge from this crisis, yes I think there could be some profit to be made in IRE stock.  However, I am not a registered financial adviser, so my opinion only counts for my portfolio.
Citigroup received significant cash, and debt relief from the US Government and the stock has performed fairly well from its lows.  However, FRE, and FNM have not performed as well! I am not yet willing to buy IRE, but I am watching closely!

Always consult with a registered financial adviser before making any investment decision. Penny stocks investing is risky and can result in entire loss of investment.

ACTC Massive Volume

Does massive volume mean a stock is good, I think not.  Things that make a stock good are the same that make a company good. Great products and the potential for profit are key to making a good company and a good stock. Buying a penny stock just because it's relatively cheap, and a dollar buys many shares is not good reason for purchasing a common stock. It looks like ACTC in recent press releases and an 8k announced clearance for the first clinical trial of its' products. There is ton of speculation about the potential of embryonic stem cells and their potential to cure illnesses. The speculation is represents promise of future demand for the products if they work.  However, there is no promise ACTC will ever produce a product which will be accepted by the FDA,or that the product will work.
Investors have made huge profits betting on early stage drug companies. Early investors in PFE, MRK, and DNDN have reaped tremendous profits.  However, there are many more investors who lost most or all of their investments in similar companies who's products ultimately failed to work.
Buying into early stage drug stocks can be very risky and entire investments could be lost. There is not guarantee that ACTC will ever produce product demanded in the market. Always consult a registered investment adviser before investing. Investing in penny stocks is very risky and can result in entire loss of investment.

Join the ACTC Stock Investors Social Network

If you are seeking the ultimate investor relations solution, visit GroupVenture.com to find out about it.  GroupVenture.com has pionered many of the new investor relations strategies in the market.

IRE, Bank of Ireland Bailout, Buy, Sell, or Hold?

As the market closed on Friday, I decided to avoid purchasing shares of IRE stock. I liked the idea of a looming bailout, and a potential bounce. However, as the bailout is unfolding shares of IRE are down significantly in pre-market trading. The market does not feel bailouts are going to be enough to bring world economies out of their current funk. While a bailout will prevent a present failure, it does not guarantee there will be a recovery and eventual return to a healthy market. I am glad I held off on a purchase of IRE shares, maybe I will pick some up on the oversold side.

Always consult a registered investment adviser before making any investment decision. Penny stocks are very risky and investing in them can result in entire loss of investment. PennyMarkets contributors are not registered investment advisers.

Advertisement
If you are seeking pink sheet, OTCBB, or penny stock investor relations please consider GroupVenture.com as your solution. Investor relations fulfillment services have changed significantly over the last few years and we have helped lead the change.

IRE Bank of Ireland, Buy, Sell, Hold?

A lot of investors are wondering about what to do with the Bank of Ireland, I'm wondering too.  If they get a good deal over the weekend, the stock could push higher, much higher. However, if the deal is unfavorable, the stock could go lower. I opted to stay away!

Always contact a registered investment adviser before making any investment decision! Penny stocks are risky, and can result in loss of investment. Only highly skilled traders, with the consult of registered investment advisers should make any pennystock investment.

Breaking Down NEOP Third Quarter 2010

 Revenues Up 6% and Gross Profit Increases 10% Year-to-date

 Neoprobe Corporation (OTCBB: NEOP), developer of diversified innovative oncology surgical and diagnostic products, announced today its consolidated 2010 results for the third quarter and for the 9 months period ending September 30, 2010.
Revenues for the 2010 third quarter were $2.3 million compared to $2.6 million for the third quarter of 2009, an 11% decrease as revenues in the third quarter of 2009 were unseasonably high and included initial stocking orders for new products.
They are saying that demand was especially high, and not to expect that every quarter.
Gross profit remained steady at $1.7 million for the third quarter of 2010 compared to the third quarter of 2009 despite the decline in revenues. Third quarter 2010 operating expenses were $3.9 million compared to $2.0 million for the third quarter of 2009, primarily as a result of the Company’s continued investment in its Lymphoseek^® drug initiative. Loss from operations for the third quarter of 2010 was $2.2 million compared to $324,000 for the third quarter of 2009.
Loss and operating expenses have increased significantly, I would like to review payroll.
2010's third quarter, Neoprobe reported a net loss attributable to common stockholders of $2.4 million, or $0.03 per share, compared to a net loss attributable to common stockholders of $25.1 million, or $0.34 per share, for the third quarter of 2009. As discussed more fully below, the net losses attributable to common stockholders for the third quarter of 2009 include significant non-cash losses aggregating $22.6 million (Alarming.) These non-cash losses were due to the extinguishment accounting treatment related to the modification of certain terms of the Company’s convertible debt, preferred stock and related warrants in July 2009 as well as mark-to-market adjustments related to derivative accounting treatment required for certain financial instruments on the Company’s balance sheet, most of which were modified in the July 2009 transaction.
Present revenues for the 9 month period ended September 30, 2010 were $7.5 million compared to $7.1 million for the same period in 2009, a 6% increase. Gross profit was $5.2 million for the nine-month period ended September 30, 2010 compared to $4.7 million for the same period in 2009, a 10% increase. Operating expenses for the nine-month period ended September 30, 2010 were $10.1 million compared to $6.1 million for the same period of 2009. Neoprobe’s loss from operations for the nine-month period ended September 30, 2010 was $4.9 million compared to $1.4 million for the same period in 2009.
Increased revenue, but even greater increase in loss.
For the nine-month period ended September 30, 2010, Neoprobe reported a net loss attributable to common stockholders of $56.1 million, or $0.70 per share, compared to a net loss attributable to common stockholders of $39.5 million, or $0.56 per share, for the same period in 2009. As discussed more fully below, the net loss attributable to common stockholders for the first nine months of 2010 and 2009 included significant non-cash losses and deemed dividends aggregating $50.4 million and $34.8 million, respectively. In 2010, these non-cash charges were primarily due to the extinguishment accounting related to the June 2010 exchange of the Company’s previous convertible debt and preferred stock for a new series of preferred stock and to mark-to-market adjustments related to derivative accounting treatment required for certain financial instruments on the Company’s balance sheet. In 2009, these non-cash charges included the extinguishment accounting related to the modification of certain terms of the Company’s convertible debt, preferred stock and related warrants and the mark-to-market adjustments related to derivative accounting treatment required for certain financial instruments on the Company’s balance sheet at that time.
Brent Larson, Neoprobe’s Senior Vice President and CFO, said, “Revenue increased on a year-to-date basis despite being lower for the quarter than in the prior year. Third quarter 2009 revenues were unseasonably high and included some initial stock orders on new products. More importantly perhaps than the year-to-date revenue increase, our gross margins have continued to improve. For the third quarter of 2010, gross margin rose to 73% of revenue compared to 64% for the third quarter of 2009 due to the receipt of grant funds, favorable pricing and lower material costs. This positive margin movement in the third quarter contributed to an overall increase in our year-to-date gross margin of 69% for the nine months ended September 30, 2010 compared to 67% for the same period in the prior year. We are pleased with our ongoing efforts to effectively manage our device business coupled with the non-dilutive contributions that our grant application efforts are starting to provide.”
I hope the business module does not include grant money, the Government is broke.
David Bupp, Neoprobe’s President and CEO, said, “Our operating expenses during the first nine months of 2010 increased as a direct result of our progress in clinical, manufacturing and regulatory activities related to our Lymphoseek drug initiative. We put in a great deal of effort in 2010 to be in a position to file our new drug application (NDA) for Lymphoseek. That effort has served us well as we now expect to file the NDA shortly following the completion of patient enrollment in our ongoing NEO3-09 Phase 3 clinical trial in patients with breast cancer or melanoma.”
“We are pleased with the progress we’ve made with the clinical and regulatory pathway for Lymphoseek,” Bupp continued. “We are also continuing our efforts to move our biologic development activities ahead to support a second advanced-stage clinical program with RIGScan^™ CR. We have successfully completed the re-characterization of the RIGScan CR biologic agent and are now preparing an investigational new drug (IND) amendment and a Phase 3 clinical protocol to support the ongoing clinical development program.”
The following are some of the milestones achieved by Neoprobe so far in 2010:

• Completion of a successful meeting with FDA to review the Phase 3 (NEO3-05) clinical study results and development plan discussion to support a NDA submission for Lymphoseek as a lymphatic-tissue tracing agent;
• Completion of successful pre-NDA dialogue with FDA on Lymphoseek pre-clinical data;
• Completion of successful pre-NDA dialogue with FDA on Lymphoseek chemistry, manufacturing and control data;
• Election of two new directors to Neoprobe’s Board, bringing significant drug industry and corporate development expertise to the Company’s leadership;
• Completion of exchange transactions that converted all of the Company’s outstanding debt to equity;
• Initiation of a third Phase 3 Lymphoseek clinical study in patients with breast cancer or melanoma to support the filing of the NDA with the potential to expand Lymphoseek’s product labeling;
• Achieved revenue and gross margin increases of 6% and 10%, respectively, for the first nine months of 2010 over 2009;
• Completion of preliminary RIGS^® development activities including transfer of biologic license application to CDER and preparation of an IND for the biologic product;
• Received notice of grant awards totaling over $1.2 million to support Lymphoseek development through non-dilutive funding;
• Completion of a pre-NDA meeting for Lymphoseek clarifying the regulatory pathway for Lymphoseek approval;
• Filed a complete response to the open biologic license application (BLA) for RIGScan CR;
• Filing of a shelf registration on Form S-3 to allow the Company to raise capital as necessary through the sale of up to $20 million in a primary offering of securities to provide us with additional financial planning flexibility and to support the diversification of our share ownership to new institutions; and
• Completion of a $6 million equity financing for working capital purposes and to support ongoing development efforts.

“In summary, our gamma detection device business continues to demonstrate positive performance,” Bupp continued. “We had completed preparation of the Lymphoseek NDA last month without the clinical data from NEO3-09. Since FDA would like the data filed with the primary NDA, we may have the opportunity to launch the product with the enhanced labeling. We are encouraged with the biologic characterization information for the RIGS technology obtained to date. Lastly, we believe our recently completed financing should buoy investor confidence regarding our ability to both reach our near-term milestones such as the commercialization of Lymphoseek and to take critical steps toward our longer term product development goals regarding RIGScan.”
Under the applicable accounting rules for complex financial instruments, embedded features in certain of the Company’s notes and preferred stock and the warrants to purchase common stock that have been issued from time to time have been considered derivative liabilities because these instruments contained language that provided for the resetting of the instruments’ exercise/conversion prices in the event that the Company issued common stock at prices below the exercise/conversion prices of the respective instruments. Treatment of these instruments as derivative liabilities resulted in them being required to be reflected on the Company’s balance sheet at their fair values (i.e., marked to market) based on certain assumptions, including the trading price of the Company’s common stock. As the share price of the Company’s common stock increased over a given period, significant mark-to-market adjustments were recorded as non-cash expenses in the Company’s statements of operations. Neoprobe’s management believes that the inclusion of such mark-to-market adjustments in the Company’s financial results does not appropriately communicate the results of the Company’s operating performance and development activities to our investors. As a result, Neoprobe’s management believes the ability of investors to analyze Neoprobe’s business trends and to understand Neoprobe’s performance may be better served from reviewing certain operational measures such as revenues, development expenses and income (loss) from operations.
On July 24, 2009, Neoprobe agreed with the holder of a majority of the instruments with derivative characteristics, Platinum-Montaur Life Sciences, LLC (Montaur), to eliminate the price reset features that had substantially caused the derivative treatment of the instruments thereby permitting the Company to effectively extinguish the majority of its derivative liabilities. During the third quarter of 2009, the Company recorded $6.3 million in mark-to-market adjustments related to movement in the price of the Company’s common stock. This contributed to a net total mark-to-market adjustment of $18.5 million being recorded for the first three quarters of 2009. As a result of the extinguishment treatment associated with the elimination of the price reset features, the Company recorded $16.2 million in non-cash loss on the extinguishment during the third quarter of 2009 and reclassified approximately $27 million in derivative liabilities to additional paid-in capital.
During June 2010, Neoprobe’s primary investor, Montaur, agreed to exchange all $10 million of its outstanding 10% senior secured convertible notes and all $3 million of its perpetual convertible preferred stock for a single new series of preferred stock convertible into 32.7 million common shares. Under the terms of the transaction, Montaur’s $7 million Series A Convertible Secured Note (originally convertible into 17.1 million common shares), $3 million Series B Convertible Note (originally convertible into 8.3 million common shares) and Series A Convertible Preferred Stock (originally convertible into 6.0 million common shares) were exchanged for Series B Convertible Preferred Stock (the Series B Preferred, convertible into a total of 32.7 million shares). As part of the consideration for the conversion, Neoprobe “prepaid” interest and dividends due through the original note maturity in December 2011 by agreeing to issue Series B Preferred which is convertible into 1.3 million shares of common stock on the conversion of the new Series B Preferred. The Series B Preferred is convertible at the option of Montaur but carries no dividend and has no liquidation preference over the common stock. The Series A Convertible Preferred Stock was convertible at the option of Montaur and paid an 8% dividend until converted. Under the applicable accounting rules for financial instruments, the exchange transactions were accounted for as extinguishments of the old instruments which resulted in the Company recording non-cash losses on extinguishment of all of the Company’s secured debt of $41.7 million related to debt instruments and a deemed dividend of $8.0 million related to the retirement of the Series A Preferred Stock. These charges accounted for the vast majority of the losses attributable to common stockholders for the nine-month period ended September 30, 2010, respectively. Excluding these non-cash losses, we would have reported losses attributable to common stockholders $0.08 per share for the nine-month period ended September 30, 2010.
Neoprobe’s President and CEO, David Bupp, Senior Vice President, Pharmaceutical Research and Clinical Development, Dr. Frederick Cope, and Senior Vice President and CFO, Brent Larson, will provide a business update and discuss the third quarter of 2010 during a conference call with the investment community scheduled for later this afternoon at 4:30 PM ET. The conference call can be accessed as follows:

Conference Call Information
TO PARTICIPATE LIVE:					TO LISTEN TO A REPLAY:
Date:		November 10, 2010			Available until:		November 24, 2010
Time:		4:30 PM ET			Toll-free (U.S.) Dial in # :		877-660-6853
					International Dial in # :		201-612-7415
Toll-free (U.S.) Dial in # :		877-407-8033			Replay Passcodes:
International Dial in # :		201-689-8033			Account #:		286
					Conference ID #:		360421

About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe^® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek^® and RIGScan^® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com